1) What implications did the lack of inclusion of clean needles in the prevention package have for trial results?
Clean needle is one of prevention method for HIV prevention package. Clinical trial phase 3 for efficacy should control any factors that may effect with study. This study did not provide clean needle which the ways of HIV infection for IDU are sharing needle and sex. I think that lack of clean needles induce to trust of trial result. We do not know that control have sharing needle more than case or not? If we provide clean needle in 2 groups, it will fair for conclusion that this factor not effect the result. It is same as condom use that is provided by study, using condom depend on participant chose. If researcher able to provide complete of prevention package for participant, it can prove efficacy of study.
2) How can researchers engage stakeholders to better negotiate prevention packages that combine various arrays of options tailored to the needs of diverse subgroups?
Researcher should have formative research and stakeholder mapping for survey opinion of them. Researcher should offer many ways and possibility that will do in study and receive comment and suggestion from stakeholder. If researcher have imperative that can not operate, they can consult with community or stakeholder about it. Researcher should have consultation meeting and have conclusion for meeting. I think that stakeholder accept study if researcher try to tailor study in the best way. It not need to do all things that stakeholder prefer but should try to do and adjust as the way that they prefer.
